High-Grade Toxicity Rates Influence Choice of IO in Melanoma
Source: Targeted Oncology, April 2025
During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune checkpoint inhibitor regimens in melanoma including alternate dosing strategies.
DISCUSSION QUESTION
What is the tolerability and ease of toxicity mitigation/ management of first-line systemic therapy for metastatic melanoma such as:?
- PD-1 inhibitor monotherapy (e.g., pembrolizumab [Keytruda] or nivolumab [Opdivo])?
Combination therapy ? - Nivolumab + ipilimumab? (Yervoy)
- Nivolumab/relatlimab (Opdualag)
James W. Smithy, MD, MHS: If you think back to all your patients who have gotten PD-1 monotherapy vs combination therapy, was one much easier than the other? Do you think nivolumab/ipilimumab is always much harder to give?